Contract Research (CRO), Biostatistics and Statistical Programming, External Committee Organization and Management, Clinical Development, Data Management, Medical Writing, and Project Management

Edgerton Data Consulting assists pharmaceutical, biotech, and medical device company sponsors with CRO selection and clinical trials oversight to ensure data management, biostatistics, and CDISC deliverables are timely, complete, and accurate.

Experienced Board Member, CEO and senior executive with proven ability to build, develop and grow international businesses. A highly strategic and results focused visionary leader for building and developing early stage, turn-around, and established companies. Repeated success in leading early stage and established companies to the next level of growth and expansion. Extensive and diverse experience that provides valuable perspectives and insights to Boards and corporate management across the company in setting vision, focus, goals, and strategies that produce the best possible results. Balancing drive and passion for growth with fiscal responsibility while generating the highest possible ROI.

Global experience in drug and device clinical development/safety monitoring, business development, regulatory interactions and public-private partnerships;board-certified neurologist/epileptologist;patient advocate; clinical and industry consultant.

Chris is the Principal Consultant at Xyzagen. Xyzagen is a drug discovery and clinical pharmacology consulting and services firm. Xyzagen, provides consulting, PK modeling, and nonGLP rodent pharmacology, bioanalysis and PK in their laboratory space.

Quality Assurance and Compliance; GCP/GLP/GCLP/GMP/CSV/Part 11; Training, auditing, SOPs; drugs, devices, biologics, dietary supplements

If you’re a visionary leader at a growth stage biopharma company, I help you identify a calculated and informed path to scale — one that mitigates risk, maximizes value, and capitalizes on your existing successes.

My frameworks provide a proven path to sustainable growth and enhanced enterprise value by overcoming common challenges, such as:

-Revenue plateaus
-Operational disruption
-Risk exposure

This stops leaders of biopharma companies from achieving:

-Sustainable growth
-Operational scalability
-Proper risk identification and management

📈 HOW I GET RESULTS FOR MY CLIENTS

As a trusted Business Advisor with decades of experience in the life sciences sector, I help small to midsize Biopharma companies achieve sustainable growth, accelerate time to market, and mitigate risks - allowing industry leaders to put their stamp on their company’s future!

→ Maximize the value of your acquisition or strategic alliance, expedite functional due diligence and time to close, and integrate seamlessly.

→ Accelerate time to market and maximize your enterprise value.

→ Mitigate risk and limit exposure that is inevitable in the growth lifecycle of your company.

✅ WHO I WORK WITH

Founders and Executives of growth stage Biopharma companies who are:

-Balancing aggressive growth targets and practicalities of limited resources
-Looking to maximize the value of a strategic acquisition or industry alliance
-Concerned about potential operational risks through the growth lifecycle
-Working to improve enterprise value to attract further investment